Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Boehringer Ingelheim
Dow
Moodys
AstraZeneca

Last Updated: October 17, 2019

DrugPatentWatch Database Preview

Claims for Patent: 6,147,279

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,147,279
Title: Inhibition of gene expression
Abstract:A method of inhibiting gene expression is described. The method, which affects enzymatic activity in a plant. The method includes expressing in a plant, or a cell, a tissue or an organ thereof, a nucleotide sequence wherein the nucleotide sequence codes, partially or completely, for an intron in an antisense orientation; and wherein the nucleotide sequence does not contain a sequence that is antisense to an axon sequence normally associated with the intron.
Inventor(s): Poulsen; Peter (Copenhagen, DK)
Assignee: Danisco A/S (Copenhagen, DK)
Application Number:08/981,803
Patent Claims:1. A method of reducing the activity of a potato starch branching enzyme in a plant or a cell, a tissue or an organ thereof comprising expressing in the plant, or the cell, the tissue or the organ thereof, a nucleic acid molecule encoding antisense RNA to an intron associated with a genomic sequence encoding said enzyme; wherein the nucleic acid molecule does not encode antisense RNA to an exon of the genomic sequence.

2. The method of claim 1 wherein the levels of amylopectin are reduced or the composition of starch is changed.

3. The method according to claim 1 wherein the nucleic acid molecule encodes an antisense RNA to intron 1 of potato starch branching enzyme.

4. The method according to claim 1 wherein the nucleic acid molecule comprises the sequence shown as ally one of SEQ. ID. No. 15 to SEQ. ID. No. 27.

5. The method according to claim 1 wherein the nucleic acid molecule is expressed by a promoter having a sequence comprising the sequence shown as SEQ. ID. No. 14.

6. The method according to claim 3 wherein the nucleic acid molecule is expressed by a promoter having a sequence comprising the sequence shown as SEQ. ID. No. 14.

7. An isolated nucleic acid molecule comprising the nucleotide sequence shown as any one of SEQ. ID. No. 15 to SEQ. ID. No. 27.

8. A vector comprising the nucleic acid molecule according to claim 7.

9. A transgenic plant comprising an isolated nucleic acid molecule encoding antisense RNA to an intron associated with a genomic sequence encoding a potato starch branching enzyme normally expressed by the cell, the tissue or the organ; wherein the nucleic acid molecule does not encode antisense RNA to an exon of the genomic sequence.

10. A transgenic plant comprising an isolated nucleic acid molecule according to claim 7.

11. pBEA8 (NCIMB 40753) or pBEA9 (NICMB 40815).

12. A method of expressing a potato starch branching enzyme in a plant comprising expressing a first nucleic acid molecule coding for the potato starch branching enzyme; and expressing a second nucleic acid molecule; wherein second nucleic acid molecule encodes an antisense RNA to an intron associated with a genomic sequence encoding said potato starch branching enzyme; wherein the second nucleic acid molecule does not encode antisense RNA to an exon of the genomic sequence.

13. The method according to claim 12 wherein the second nucleic acid molecule encodes an antisense RNA to intron 1 of potato starch branching enzyme.

14. A method of reducing starch branching enzymatic activity in a plant, or a cell, a tissue or an organ thereof, comprising expressing in the plant, or the cell, the tissue or organ thereof a nucleic acid molecule encoding antisense RNA to intron 1 of the potato starch branching enzyme, optionally under the control of the promoter of the potato starch branching enzyme.

15. The method according to claim 14 wherein levels of amylopectin are affected or the composition of starch is changed in the plant, or the cell, tissue or organ thereof.

16. The method according to claim 14 wherein the nucleic acid comprises the sequence shown as any one of SEQ. ID. No. 15 to SEQ. ID. No. 27.

17. The method according to claim 14 wherein the nucleic acid molecule is expressed by a promoter having a sequence comprising the sequence shown as SEQ ID NO. 14.

18. The method according to claim 16 wherein the nucleic acid molecule is expressed by a promoter having a sequence comprising the sequence shown as SEQ ID NO. 14.

19. A method of reducing starch branching enzymatic activity in a starch producing plant or a cell, a tissue, or an organ thereof, comprising expressing in the starch producing plant, the cell, the tissue or the organ thereof a nucleic acid molecule encoding antisense RNA to intron 1 of the potato starch branching enzyme, optionally under the control of the promoter of the potato starch branching enzyme.

20. The method according to claimed 19 wherein levels of amylopectin are affected or the composition of starch is changed in the starch producing plant, or the cell, tissue or organ thereof.

21. The method according to claim 19 wherein the nucleic acid comprises the sequence shown as any one of SEQ. ID. No. 15 to SEQ. ID No. 27.

22. The method according to claim 19 wherein the nucleic acid molecule is expressed by a promoter having a sequence comprising the sequence shown as SEQ ID NO. 14.

23. The method according to claim 21 wherein the nucleic acid molecule is expressed by a promoter having a sequence comprising the sequence shown as SEQ ID NO. 14.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9514435Jul 14, 1995
PCT Information
PCT FiledJuly 12, 1996PCT Application Number:PCT/EP96/03052
PCT Publication Date:February 06, 1997PCT Publication Number:WO97/04112

Details for Patent 6,147,279

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Danisco A/S (Copenhagen, DK) 2015-07-14 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Danisco A/S (Copenhagen, DK) 2015-07-14 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Danisco A/S (Copenhagen, DK) 2015-07-14 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
McKesson
Merck
Express Scripts
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.